Eli Lilly and Company

vorige Seite Seite 1 von 4 nächste Seite

New Online Tool Helps Patient Advocates Navigate Medicines Development and Evaluation Process

A new online, interactive training programme designed to help patient advocates better influence decisions related to access to new medicines was launched today in advance of the 6th Global Patient Congress …

OTE0002
24.03.2014 10:12
 

Lilly veröffentlicht Aktualisierung über Tätigkeiten im Corporate-Responsibility-Bereich

- Unternehmen meldet Fortschritte bei zahlreichen ökonomischen, ökologischen und sozialen Leistungskennzahlen

OTS0167
03.12.2012 13:03
 

Lilly Global gibt Mitarbeitern mehr Möglichkeiten zu gemeinnütziger Arbeit

Zum ersten Mal können Mitarbeiter von Eli Lilly and Company weltweit mehr als 800 Graswurzelprojekte weltweit unterstützen, wobei die Eli Lilly and Company Foundation ihre Spenden verwaltet - was den Wert …

OTS0002
26.07.2011 01:59
 

Lilly CEO Says Industry, Public Policy Must Pave Way For Innovation

A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases with potentially devastating personal and financial …

OTE0005
10.02.2011 10:17
 

Mortality Data Presented for Patients Treated with Efient(R)/Effient(R) (Prasugrel) Who Underwent Isolated Coronary Artery Bypass Surgery

New results from an observational substudy from TRITON-TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with …

OTE0007
16.11.2010 16:03
 

Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials

Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing …

OTE0006
17.08.2010 14:01
 

Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor

Eli Lilly and Company (NYSE: LLY) announced today that Steven M. Paul, M.D., executive vice president, science and technology, and president, Lilly Research Laboratories, will retire from Lilly effective …

OTE0006
13.11.2009 15:11
 

Eight out of 10 People Diagnosed With Heart Disease Consider Their Diagnosis a 'Wake-Up Call'

- Your Heart: New Start initiative launched to provide heart patients and their carers with information about nutrition, fitness and medication adherence

OTE0012
31.08.2009 16:37
 

World Heart Federation, Daiichi Sankyo and Lilly Partner to Improve Cardiovascular Health

The World Heart Federation, Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced today that they have partnered to improve cardiovascular health internationally.

OTE0002
31.03.2009 06:07
 

New Data Show Duloxetine Maintained Pain Reduction for More Than Six Months in Patients With Diabetic Peripheral Neuropathic Pain

- Study with duloxetine evaluating long-term pain reduction in treatment of DPNP is first to exceed three months

OTE0012
19.08.2008 16:20
 

Phase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimer's Disease

- Findings lead to decision to start Phase III pivotal study of LY2062430 in 2009

OTE0007
30.07.2008 22:22
 

Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease

- Late-stage IDENTITY study of once-daily, oral agent is now enrolling patients

OTE0008
31.03.2008 10:04
 

Lilly gibt Weltgesundheitsorganisation 4,4 Mio. US-Dollar für Ausbau von MDR-TB-Programm

Eli Lilly and Company kündigte heute die Vergabe von Forschungsgeldern in Höhe von 4.384.000 USD an die Weltgesundheitsorganisation (WHO) an.

OTS0055
12.03.2008 09:08
 

FORSTEO(R) erhält positive Einschätzung des Europäischen Ausschusses für Humanarzneimittel (CHMP) zur Behandlung von glukokortikoidinduzierter Osteoporose

- Im Falle der Zulassung stände der knochenbildende Wirkstoff für Osteoporose einer neuen Patientenpopulation zur Verfügung

OTS0001
23.02.2008 00:02
 
vorige Seite nächste Seite